✅ This trial is currently recruiting volunteers
If you think you might be eligible, speak to your GP or specialist about this trial before applying.
Status
Recruiting
Phase
PHASE2
Participants
ALL
Age Range
18 Years+
About This Trial
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
Who Can Join?
Inclusion Criteria: * Diagnosis of CD established at least 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of CD * Moderately to severely active CD based on CDAI criteria, defined as baseline (Week I-0) CDAI score >=220 but =4, or mean daily AP score >=2 * Moderately to severely active CD based on SES-CD criteria assessed by baseline (Week I-0) endoscopic evidence of active ileal and/or colonic CD as assessed during central review of the screening video ileocolonoscopy defined as a SES-CD >= 6 for participants with colonic or ileocolonic disease, and SES-CD >= 4 for participants with isolated ileal disease, based on the presence of ulceration in any 1 of the 5 ileocolonic segments * A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta-hCG) at screening and a negative urine pregnancy test at Week…
⚠ Always speak to your doctor before applying to any clinical trial.
More Gut & Digestion Trials
Recruiting PHASE3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn’s Disease…
Recruiting PHASE3A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and…
Recruiting PHASE3A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis